ype 2 diabetes increases the risk of coronary heart disease t least by 2to 3-fold. Patients with type 2 diabetes without history of myocardial infarction (MI) have the same risk or fatal MI as nondiabetic subjects with a history of MI 1,2). Moreover, type 2 diabetic patients with previous MI re even more susceptible to coronary events and need all vailable evidence-based tools for cardiovascula...

AM1 calculations on equilibrium and transition state geometries of keto and enol forms of glitazones were carried out and compared with those of some carbonyl compounds. The results show that the energy requirements for enolisation of glitazones are much higher than the standard carbonyl systems. Neither the ring system, nor the additional functional groups in thiazolidinedione terminal ring fa...

As the incidence of diabetes mellitus (DM) continues to increase worldwide, more diabetic patients will be presented for surgery and anesthesia. This increase of DM is a consequence of the rise in new patients of type 2 DM, and is likely attributable to rapid economic development, improved living standards, aging population, obesity, and lack of exercise. The primary goal of management in DM is...

OBJECTIVE Thiazolidinediones (TZDs) are known to increase the risk of heart failure in patients with type 2 diabetes. We aimed to evaluate the magnitude of the risk of heart failure with TZDs and classify this adverse effect under the novel dose-time-susceptibility system. RESEARCH DESIGN AND METHODS Evidence from randomized trials, controlled observational studies, anecdotal case reports, ca...

OBJECTIVE To determine the effect of thiazolidinediones (TZDs) on experimental retinal neovascularization. METHODS The ability of the TZDs troglitazone and rosiglitazone maleate (1-20 micromol/L) to inhibit retinal endothelial cell (REC) proliferation, migration, tube formation, and signaling was determined in response to vascular endothelial growth factor (VEGF). In vivo studies were perform...